V-Tech, a Midrand – based pharmaceutical company, has recently completed phase 2 of its facility upgrade by unveiling its new modern manufacturing facility. Well known for the pioneering work done in compounding veterinary medicines, the company now aims to transfer this expertise to manufacturing medicines for use in human pharmaceutical and consumer health products.
The South African government unveiled its national strategy to support investment in the pharmaceutical industry in 2012. Various initiatives were launched to support the local capacity to manufacture medicines within South Africa by the Minister of Health and the DTI, resulting in substantial growth of companies like Aspen. In line with this national strategy, V-Tech Pty Ltd, a privately owned South African company, was recently awarded a level 6 BBBEEE certificate and invested to expand its capacity to produce medicines locally in South Africa.
“We see the future in investing and producing international standard medication in South Africa” Dr Johan Oosthuyse, V-Tech CEO. “We have an incredible pool of talent and expertise that can benefit the country by manufacturing pharmaceutical products for veterinary and human use locally. Although South Africa is faced with many challenges, it offers equal amount of opportunities. Together with our investment partners, V-Tech has taken up these challenges to now offer a first-world pharmaceutical manufacturing facility in South Africa as part of the national strategy to increase capacity in this industry.”
The new facility offers various different manufacturing lines to produce medicines ranging from ointment and tablets to injectables. It applies international GMP and is ISO 9001 certified to ensure the required quality control is attended to.
A recent visit by Prof. Banie Penzhorn, Managing Director of the South African Veterinary Association, had the following to say “I had the opportunity of visiting V-Tech’s new production facility recently. It really made a good impression: light and airy, with lots of glass. In the planning, care was taken not only to minimise the risk of cross-contamination of products during the production phase, but, more importantly, that the employees will have a safe and pleasant working environment.”
The new plant was designed by the international consulting firm, Royal Haskoning DHV and the environmental control air system was designed and installed by Shamus Rennie. The facility is equipped with advanced technology processes to produce high-quality pharmaceutical products in a climate-controlled environment.
This substantial investment deepens V-Tech’s growing research and development, manufacturing and commercial presence in Southern Africa. The new facility increased the current manufacturing floor space with about 1,100m2. It also created new employment opportunities for various positions ranging from quality assurance, production, and regulatory affairs to administration services. By offering employees ideal working conditions, the project was designed with the future working conditions of the V-Tech employees in mind. In addition to light and spacious designs, all the facilities have been developed to limit direct exposure of operators to the products to the absolute minimum.
“Over the last 10 years V-Tech has grown from strength to strength through building trusted relationships with our clients. In January 2015 we’ll celebrate the opening of our new facility, marking another milestone for V-Tech. We are committed to the Animal Health industry in South Africa and look forward to building stronger partnerships with our current and new customers, and increasing the range that we can offer them.” David Gerber, Chief Technical Officer at V-Tech.